Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -36.80% is 56% above its 5-year average of -83.39%, near the high end of its 5-year range (-275.21%–-13.96%).
0.70% below its 12-month average of -36.55%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -35.85%.
NET PROFIT MARGIN
-36.80%
NET PROFIT MARGIN AVG TTM
-36.55%
NET PROFIT MARGIN AVG 3Y
-29.49%
NET PROFIT MARGIN AVG 5Y
-83.39%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-0.70%
CURRENT VS 3Y AVG
-24.78%
CURRENT VS 5Y AVG
+55.87%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.26%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-14053.85%
vs the sector median at left
RxSight, Inc.
Market Cap
$191.67M
Net Profit Margin
-36.80%
TTM Avg
-36.55%
3Y Avg
-29.49%
5Y Avg
-83.39%
Market Cap
$192.56M
Net Profit Margin
0.00%
TTM Avg
-122.98%
3Y Avg
-61.49%
5Y Avg
-40.99%
Market Cap
$189.50M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$184.04M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$183.17M
Net Profit Margin
-6559.27%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$200.77M
Net Profit Margin
-2885.33%
TTM Avg
-3778.66%
3Y Avg
-1961.34%
5Y Avg
-1307.56%
Market Cap
$201.70M
Net Profit Margin
-850.13%
TTM Avg
-398.77%
3Y Avg
-257.91%
5Y Avg
-325.14%
Market Cap
$180.89M
Net Profit Margin
3202.50%
TTM Avg
1601.25%
3Y Avg
554.42%
5Y Avg
279.00%
Market Cap
$180.99M
Net Profit Margin
0.00%
TTM Avg
-2904.41%
3Y Avg
-1452.20%
5Y Avg
-968.14%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| RxSight, Inc. (RXST) | $191.67M | -36.80% | -36.55% | -29.49% | -83.39% |
| Zentalis Pharmaceuticals, Inc. (ZNTL)vs › | $192.56M | 0.00% | -122.98% | -61.49% | -40.99% |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $189.50M | 0.00% | 0.00% | 0.00% | 0.00% |
| AN2 Therapeutics, Inc. (ANTX)vs › | $184.04M | 0.00% | 0.00% | 0.00% | 0.00% |
| Canton Strategic Holdings Inc (CNTN)vs › | $183.17M | -6559.27% | 0.00% | 0.00% | 0.00% |
| Surrozen, Inc. (SRZN)vs › | $200.77M | -2885.33% | -3778.66% | -1961.34% | -1307.56% |
| Alector, Inc. (ALEC)vs › | $201.70M | -850.13% | -398.77% | -257.91% | -325.14% |
| Oramed Pharmaceuticals Inc. (ORMP)vs › | $180.89M | 3202.50% | 1601.25% | 554.42% | 279.00% |
| Compass Therapeutics, Inc. (CMPX)vs › | $180.99M | 0.00% | -2904.41% | -1452.20% | -968.14% |
| Exagen Inc. (XGN)vs › | $202.49M | -26.61% | -28.57% | -51.55% | -50.26% |
Operating Margin
-43.2%
Net Profit Margin
-36.8%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -35.85% |
| 2026-03-31 | -51.42% |
| 2025-12-31 | -28.06% |
| 2025-09-30 | -32.35% |
| 2025-06-30 | -35.04% |
| 2025-03-31 | -21.61% |
| 2024-12-31 | -14.77% |
| 2024-09-30 | -13.96% |
| 2024-06-30 | -17.42% |
| 2024-03-31 | -30.83% |
| 2023-12-31 | -32.11% |
| 2023-09-30 | -40.48% |
| 2023-06-30 | -66.33% |
| 2023-03-31 | -75.54% |
| 2022-12-31 | -97.03% |
| 2022-09-30 | -133.32% |
| 2022-06-30 | -147.29% |
| 2022-03-31 | -196.78% |
| 2021-12-31 | -186.73% |
| 2021-09-30 | -219.03% |
| 2021-06-30 | -275.21% |
| 2021-03-31 | -195.32% |
| 2020-12-31 | 535.10% |
| 2020-09-30 | 735.35% |
| 2020-06-30 | -476.05% |
| 2020-03-31 | -571.40% |
